TNBC Clinical Trials

4 recruiting

TNBC Trials at a Glance

33 actively recruiting trials for tnbc are listed on ClinicalTrialsFinder across 6 cities in 13 countries. The largest study group is Phase 2 with 13 trials, with the heaviest enrollment activity in Nashville, Shanghai, and San Antonio. Lead sponsors running tnbc studies include Fudan University, Peking University Cancer Hospital & Institute, and Cedars-Sinai Medical Center.

Browse tnbc trials by phase

Treatments under study

About TNBC Clinical Trials

Looking for clinical trials for TNBC? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new TNBC trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about TNBC clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 33 trials

Recruiting
Not Applicable

Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy

Melanoma (Skin Cancer)Renal Cell Carcinoma (Kidney Cancer)Breast Cancer (Triple Negative Breast Cancer (TNBC))
Jessica Mezzanotte Sharpe25 enrolled1 locationNCT07555210
Recruiting

Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer

TNBC - Triple-Negative Breast Cancer
Fudan University300 enrolled1 locationNCT07551050
Recruiting
Phase 2

Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation

Breast CancerTNBC - Triple-Negative Breast Cancer
Stephen Shiao35 enrolled1 locationNCT05491226
Recruiting
Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Esophageal CancerGastric CancerCervical Cancer+5 more
Genentech, Inc.450 enrolled41 locationsNCT05581004
Recruiting
Phase 2

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

Metastatic Breast CancerHER2-negative Breast CancerMetaplastic Breast Carcinoma+1 more
The Methodist Hospital Research Institute36 enrolled3 locationsNCT05660083
Recruiting
Phase 2

Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

TNBC - Triple-Negative Breast CancerEarly Stage Triple-Negative Breast CarcinomaTNBC
Cedars-Sinai Medical Center34 enrolled4 locationsNCT07017673
Recruiting
Phase 1

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

Gastric CancerAdvanced Solid TumorTNBC - Triple-Negative Breast Cancer+1 more
SillaJen, Inc.260 enrolled15 locationsNCT05768932
Recruiting
Phase 2

LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer

Triple Negative Breast Cancer (TNBC), Early Setting
Universitaire Ziekenhuizen KU Leuven356 enrolled10 locationsNCT06831955
Recruiting
Phase 2

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Breast CancerBreast NeoplasmsHER2-negative Breast Cancer+6 more
QuantumLeap Healthcare Collaborative5,000 enrolled42 locationsNCT01042379
Recruiting

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

Breast CancerTNBC - Triple-Negative Breast CancerEarly Stage Breast Cancer+2 more
Tempus AI900 enrolled12 locationsNCT07211178
Recruiting
Phase 1Phase 2

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

TNBC - Triple-Negative Breast CancerAdvanced Solid TumorsNSCLC+3 more
Tubulis GmbH250 enrolled16 locationsNCT06657222
Recruiting
Not Applicable

NearWave Optical Molecular Monitoring

Breast CancerHER2-negative Breast CancerHER2-positive Breast Cancer+2 more
Indiana University15 enrolled1 locationNCT06744465
Recruiting

Immunotherapy-related CRP Kinetics in Early and Metastatic Triple-negative Breast Cancer

TNBC - Triple-Negative Breast Cancer
University Hospital Tuebingen225 enrolled1 locationNCT05914961
Recruiting
Phase 3

SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC

TNBC - Triple-Negative Breast Cancer
West China Hospital318 enrolled1 locationNCT06627712
Recruiting
Phase 2

Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)

TNBC - Triple-Negative Breast Cancer
First Affiliated Hospital of Zhejiang University37 enrolled2 locationsNCT07351487
Recruiting
Early Phase 1

A Prospective, Open-label, Single-arm, Exploratory Clinical Trial to Evaluate the Safety and Tolerability of 225Ac-TR2205 Injection in Patients With Triple-negative Breast Cancer.

Advanced Metastatic Triple-negative Breast Cancer (mTNBC)
Xiaorong Sun15 enrolled1 locationNCT07340424
Recruiting
Phase 1

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

Gastric CancerCervical CancerCancer+7 more
Rondo Therapeutics149 enrolled2 locationsNCT07218003
Recruiting
Phase 2

PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer.

TNBC - Triple-Negative Breast Cancer
Jules Bordet Institute20 enrolled1 locationNCT06059469
Recruiting
Phase 3

A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer

TNBC - Triple-Negative Breast Cancer
Fudan University606 enrolled1 locationNCT05862064
Recruiting

Role of the Immune Environment in Response to Therapy in Breast Cancer

Breast CancerHER2-negative Breast CancerER Positive Breast Cancer+1 more
Abramson Cancer Center at Penn Medicine300 enrolled1 locationNCT05396612